Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
Philip Stephen WellsAnthonie W A LensingLloyd HaskellBennett LevitanFrançois LalibertéMichael DurkinVeronica AshtonYongling XiaoConcetta CriveraDominique LejeuneJeff ScheinPatrick LefebvrePublished in: Journal of medical economics (2018)
Total healthcare costs were estimated to be lower for patients continuing rivaroxaban therapy compared to those receiving placebo in VTE patients who had completed 6-12 months of VTE treatment.